Evidence map›Paper›PMID 30471051›Full record

ArticleJournal of neuro-oncology2018

Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV.

Kristin Marie Knudsen-Baas, Tom Børge Johannesen, Tor Åge Myklebust, Jan Harald Aarseth, Jone Furlund Owe, Nils Erik Gilhus, Anette Margrethe Storstein

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Depression and anxiety in glioma patients.Neuro-oncology practice · 2023
    Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Kristin Marie Knudsen-BaasDepartment of Clinical Medicine, University of Bergen, Post Box 7804, 5020, Bergen, Norway. Kristin.Knudsen-Baas@uib.no.ORCID http://orcid.org/0000-0002-7805-1831
Tom Børge JohannesenDepartment of Registration, Cancer Registry of Norway, Ullernchausseen 64, Oslo, 0379, Norway.
Tor Åge MyklebustDepartment of Registration, Cancer Registry of Norway, Ullernchausseen 64, Oslo, 0379, Norway.
Jan Harald AarsethDepartment of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
Jone Furlund OweDepartment of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
Nils Erik GilhusDepartment of Clinical Medicine, University of Bergen, Post Box 7804, 5020, Bergen, Norway.
Anette Margrethe StorsteinDepartment of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
Haukeland University Hospital · NOÅlesund Hospital · NOCancer Registry of Norway · NOUniversity of Bergen · NO

Funding

Universitetet i Bergen PhD scholarship
6 · The paper itself

Abstract

introductionGlioma is the most common intracranial primary brain tumor. Patients with glioma often suffer from epilepsy, anxiety and depression. Aims of this study were to identify risk factors for drug-treated anxiety and depression, and to determine the use of psychiatric medication in a national glioma cohort.

methodsData from the Cancer Registry of Norway on all persons diagnosed with glioma WHO grade II-IV 2004-2010 were linked with data from the Norwegian Prescription Database. Cox regression analysis was used to assess risk factors for drug-treated anxiety and depression. Standardized incidence ratios were calculated for psychiatric medication dispensed to glioma patients and compared to the general population.

resultsThe glioma cohort consisted of 1056 males and 772 females. Of the 1828 patients, 565 had glioma grade II-III, and 1263 had grade IV. The patients with glioma grade II-III who were treated with levetiracetam had an increased risk for drug-treated anxiety compared to patients without levetiracetam; hazard ratio 2.8 (95% confidence interval 1.7-4.9). Female gender increased the risk for drug-treated anxiety compared to males in patients with glioma grade IV; hazard ratio 1.5 (95% confidence interval 1.2-2.0). Antidepressants were less frequently dispensed to patients with glioma grade II-III and epilepsy than to the general population.

conclusionsPatients with glioma grade II-III on levetiracetam had an increased risk for drug-treated anxiety. The subgroup of patients with glioma grade II-III and epilepsy received less antidepressants than the general population.

Indexed as

AdultAgedAged, 80 and overAnticonvulsantsAntidepressive AgentsAnxietyBrain NeoplasmsCohort StudiesDepressionFemaleGliomaHumansLevetiracetamMaleMiddle AgedRegistriesAnticonvulsantsAntidepressive AgentsLevetiracetamAntiepileptic drugsAnxietyDepressionEpilepsyGlioma

Identifiers

PMID30471051
OpenAlexW2901553730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.